论文部分内容阅读
自1967年Shida首次用丝裂霉素C（MMC）膀同济医科大学附属同济医院泌尿外胱内灌注防治浅表性膀胱肿瘤以来，MMC已逐渐成为治疗浅表性膀胱肿瘤常用药物之一。文献报道膀胱肿瘤切除后，行MMC膀胱内灌注后，肿瘤复发率降低10％～50％[1]，但其导致的并发症发生率也有5％～50％，主
MMC has become one of the commonly used drugs for the treatment of superficial bladder tumors since 1967 when Shida was the first to treat superficial bladder tumor with intravesical instillation of mitomycin C (MMC) in Tongji Hospital Affiliated to Tongji Medical University. Reported in the literature after resection of the bladder tumor, after MMC intravesical instillation, the tumor recurrence rate decreased by 10% to 50% [1], but the resulting complication rate of 5% to 50%, the main